Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Simcere Pharmaceutical Group Limited ( (HK:2096) ) is now available.
Simcere Pharmaceutical Group Limited announced that its anti-tumor drug candidate, SIM0505, a CDH6 Antibody-Drug Conjugate, has received clinical trial approval from China’s National Medical Products Administration and the U.S. FDA for advanced solid tumors. This development may strengthen Simcere’s position in the oncology market by advancing treatments for malignant tumors such as ovarian and renal cancer, potentially reducing toxic side effects compared to traditional chemotherapies.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company, focusing on oncology, nervous system, autoimmune, and anti-infection therapeutic areas. The company aims to address significant clinical needs with future-oriented medicine, supported by its in-house R&D and strategic partnerships with innovative companies and research institutes.
YTD Price Performance: -2.68%
Average Trading Volume: 6,417,755
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: HK$17.46B
Learn more about 2096 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue